SCHEMBL29328003

SCHEMBL29328003

CCc1ccc(-c2nc3cc(NC(=O)c4cc(C#N)cnc4S(C)(=O)=O)cc(F)c3o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 7/20 0.52
▸ CEPT1 Q9Y6K0 5/20 0.45
▸ MAPT P10636 5/20 0.44
▸ TP53 P04637 4/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ CYP2C8 P10632 2/20 0.39
▸ NR1I2 O75469 1/20 0.39
▸ PPARD Q03181 1/20 0.39
▸ PPARA Q07869 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.38
▸ CETP P11597 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29328005 0.91 PPARG (0.58) PPARGCEPT1MAPTTP53SMN1; SMN2
SCHEMBL29327893 0.87 PPARG (0.57) PPARGCEPT1MAPTTP53SMN1; SMN2
SCHEMBL29327818 0.86 PPARG (0.70) PPARGMAPTTP53SMN1; SMN2POLB
SCHEMBL29327844 0.85 PPARG (0.60) PPARGCEPT1MAPTTP53SMN1; SMN2
SCHEMBL29327982 0.84 PPARG (0.46) PPARGCEPT1MAPTTP53SMN1; SMN2
SCHEMBL29327933 0.84 PPARG (0.55) PPARGCEPT1MAPTTP53SMN1; SMN2
SCHEMBL29327954 0.79 MAPT (0.45) PPARGCEPT1MAPTTP53SMN1; SMN2
SCHEMBL29327895 0.78 PPARG (0.64) PPARGCEPT1MAPTTP53SMN1; SMN2
SCHEMBL29327997 0.78 HDAC6 (0.47) PPARGMAPTTP53SMN1; SMN2KDM4E
SCHEMBL29327807 0.77 PPARG (0.56) PPARGMAPTTP53SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD PPARG 1/4885CEPT1 2386/4885MAPT 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback